Inhibitor Theraptics (INTI) Debt by Year
Inhibitor Theraptics Inc carried $37K in long-term debt against $2.4M in cash and equivalents at the end of fiscal year 2025. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Inhibitor Theraptics Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
INTI Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $37K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $2.4M-57.6% | $5.6M-36.6% | $8.8M-26.0% | $12.0M+38923.1% | $31K-59.2% | $75K-90.7% | $804K-27.5% | $1.1M+222.2% | $344K-95.0% | $6.9M+1044.8% | $601K+64.7% | $365K+168177.0% | $217-100.0% | $858K |
INTI Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $22K-58.6% | $29K-49.7% | $37K | $44K | $52K | $58K | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $516K-86.2% | $1.3M-70.1% | $2.4M-57.6% | $3.0M-53.3% | $3.7M-47.3% | $4.3M-43.7% | $5.6M-36.6% | $6.4M-33.1% | $7.1M-29.7% | $7.7M-28.8% | $8.8M-26.0% | $9.5M+17875.8% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Inhibitor Theraptics Inc financials
Frequently Asked Questions
Inhibitor Theraptics Inc carried $37K in long-term debt against $2.4M in cash and equivalents at the end of fiscal year 2025.
Inhibitor Theraptics Inc (INTI) reported $22K in long-term debt in Q2 2026. This represents a decrease of 58.6% from the same quarter a year earlier.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Inhibitor Theraptics Inc (INTI) reported on that line in every period on record.